Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer

17 Jan 2024

Abstract excerpt

PURPOSE: DNA methylation causes silencing of tumor-suppressor and differentiation-associated genes, being linked to chemoresistance. Previous studies demonstrated that hypomethylating agents (HMA) resensitize ovarian cancer to chemotherapy. NTX-301 is a highly potent and orally bioavailable HMA, in early clinical development. EXPERIMENTAL DESIGN: The antitumor effects of NTX-301 were studied in ovarian cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immune cells in cancer
Share to Epigenetics and DNA Methylation
Share to Ferroptosis and cancer prognosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38231483
DOI: 10.1158/1078-0432.ccr-23-2368

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian CancerPMID 38231483Read ↗

Imetelstat-Mediated Alterations in Fatty Acid Metabolism To Induce Ferroptosis As Therapeutic Strategy for Acute Myeloid LeukemiaSemantic proximity Read ↗

NKX2-8 deletion-induced reprogramming of fatty acid metabolism confers chemoresistance in epithelial ovarian cancerSemantic proximity Read ↗

A novel ALDH1A1 Inhibitor Blocks Platinum-Induced Senescence and Stemness in Ovarian CancerSemantic proximity Read ↗

A novel ALDH1A1 inhibitor blocks platinum-induced senescence and stemness in ovarian cancerSemantic proximity Read ↗

Metabolic consequences of erastin-induced ferroptosis in human ovarian cancer cells: an untargeted metabolomics studySemantic proximity Read ↗

Targeting Aldehyde Dehydrogenase Cancer Stem Cells in Ovarian CancerSemantic proximity Read ↗

Combinatorial targeting of menin and the histone methyltransferase DOT1L as a novel therapeutic strategy for treatment of chemotherapy-resistant ovarian cancerSemantic proximity Read ↗

Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells.Semantic proximity Read ↗

Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance.Semantic proximity Read ↗

AMH protects the ovary from doxorubicin by regulating cell fate and the response to DNA damageSemantic proximity Read ↗

Integration of epigenomic and transcriptomic profiling uncovers EZH2 target genes linked to cysteine metabolism in hepatocellular carcinomaSemantic proximity Read ↗

Artemin Stimulates Radio- and Chemo-resistance by Promoting TWIST1-BCL-2-dependent Cancer Stem Cell-like Behavior in Mammary Carcinoma CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.